Milestone Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Milestone Pharmaceuticals Inc. (MIST) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $6.08 per share as of 2021-12-31, per its 10-K filed 2023-03-29.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2023-03-29
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $6.08.
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $7.96.
- 2019-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $3.89; Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed $3.89.
- 2019-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $3.53.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2021-12-31 | $6.08 10-K · filed 2023-03-29 | |
| 2020-12-31 | $7.96 10-K · filed 2021-03-29 | |
| 2019-12-31 | $3.89 10-K · filed 2021-03-29 | $3.89 10-K · filed 2020-03-06 |
| 2019-09-30 | $3.53 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $2.00 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $1.72 10-Q · filed 2019-06-19 | |
| 2018-12-31 | $1.35 10-K/A · filed 2020-10-23 | $1.35 10-Q · filed 2019-06-19 |
| 2018-09-30 | $1.10 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $1.08 10-Q · filed 2019-08-13 | |
| 2018-03-31 | $1.08 10-Q · filed 2019-06-19 | |
| 2017-12-31 | $1.03 10-K/A · filed 2020-10-23 | $1.03 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |